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ABSTRACT
Epidermal Growth Factor (EGF) receptor overexpression, KRAS, TP53, CDKN2A 
and SMAD4 mutations characterize pancreatic ductal adenocarcinoma. This mutational 
landscape might influence cancer cells response to EGF, Transforming Growth Factor 
β1 (TGFβ1) and stromal inflammatory calcium binding proteins S100A8/A9. We 
investigated whether chronic exposure to EGF modifies in a SMAD4-dependent manner 
pancreatic cancer cell signalling, proliferation and invasion in response to EGF, TGFβ1 
and S100A8/A9. BxPC3, homozigously deleted (HD) for SMAD4, and BxPC3-SMAD4+ 
cells were or not stimulated with EGF (100 ng/mL) for three days. EGF pre-treated and 
non pretreated cells were stimulated with a single dose of EGF (100 ng/mL), TGFβ1 
(0,02 ng/mL), S100A8/A9 (10 nM). Signalling pathways (Reverse Phase Protein 
Array and western blot), cell migration (Matrigel) and cell proliferation (XTT) were 
evaluated. SMAD4 HD constitutively activated ERK and Wnt/β-catenin, while inhibiting 
PI3K/AKT pathways. These effects were antagonized by chronic EGF, which increased 
p-BAD (anti-apoptotic) in response to combined TGFβ1 and S100A8/A9 stimulation. 
SMAD4 HD underlied the inhibition of NF-κB and PI3K/AKT in response to TGFβ1 
and S100A8/A9, which also induced cell migration. Chronic EGF exposure enhanced 
cell migration of both BxPC3 and BxPC3-SMAD4+, rendering the cells less sensitive 
to the other inflammatory stimuli. In conclusion, SMAD4 HD is associated with the 
constitutive activation of the ERK and Wnt/β-catenin signalling pathways, and 
favors the EGF-induced activation of multiple signalling pathways critical to cancer 
proliferation and invasion. TGFβ1 and S100A8/A9 mainly inhibit NF-κB and PI3K/
AKT pathways and, when combined, sinergize with EGF in enhancing anti-apoptotic 
p-BAD in a SMAD4-dependent manner.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC), the 
fourth leading cause of cancer-related deaths in the US and 
the seventh worldwide [1, 2], is characterized by a complex 
mutational landscape and significant inter-tumoral genetic 
heterogeneity. Based on the results of whole genome 
sequencing and copy number variation analysis of 100 
PDAC, Waddell et al. [3] suggested to classify PDAC 
into four subtypes (stable, locally rearranged, scattered 
and unstable), the patterns of chromosome variation being 
recognized as an important mutational mechanism in 
pancreatic carcinogenesis. In addition to numerous genes 
mutated at low prevalence, the mutations of four genes 
(KRAS, TP53, SMAD4, CDKN2A) characterize PDAC. 
Highly frequent early events in PDAC are activating 
mutations of the KRAS oncogene and inactivating 
mutations of the tumor suppressor gene TP53 (more than 
90% and up to 70% of the cases, respectively), whereas 
late events, found in 30 to 50% of cases, are inactivation 
of the tumor suppressors CDKN2A and SMAD4 due to 
homozygous deletion and/or a combination of structural 
variation events with deleterious point mutations [4].
On the basis of results obtained in transgenic mouse 
models, KRAS mutation was found to be necessary for, 
but not sufficient to cause, PDAC, the further onset and 
progression of which is dependent on KRAS mutation 
combined with inactivation of tumor suppressor genes, 
TP53 or SMAD4 in particular [5, 6]. Data supporting the 
role of TP53 and SMAD4 inactivation in human PDAC 
carcinogenesis derive mainly from the study of PanINs 
precursor lesions [7]. Most of the studies conducted to 
investigate whether these mutations play a role in tumor 
progression provide evidence that SMAD4 deletion is 
a negative prognostic factor [8–13], although recently 
Dal Molin et al. [14] failed to demonstrate that somatic 
KRAS, TP53, SMAD4 and CDKN2A mutations impact 
on PDAC survival in the very long-term. This discrepancy 
may depend on the fact that PDAC behaviour not only 
depends on the genetic derangement of cancer cells, 
but is also the result of a complex interplay between 
genetically altered cancer cells and their surrounding 
microenvironment. PDAC has a highly dispersed growth 
pattern, with wide-set tumour glands in extensive 
desmoplastic stroma that encompasses inflammatory 
and stellate cells, and fibroblasts [15, 16]. Stromal 
and cancer cells influence each other through contact 
dependent and independent mechanisms, the latter being 
mediated by the release of soluble factors, which include 
cytokines, chemokines, growth factors and inflammatory 
molecules. In this scenario the epidermal growth factor 
(EGF), the transforming growth factor β1 (TGFβ1) and 
the inflammatory molecules S100A8 and S100A9 seem 
particularly relevant [17–19]. Cancer cells not only 
release EGF, but they also overexpress the EGF receptor 
(EGFR), which is recognized as the initial, indispensable 
molecular alteration in pancreatic carcinogenesis. As a 
general rule, EGF determines the activation of the MAPK/
ERK and PI3K/AKT pathways [20]. TGFβ1, produced 
by cancer and stromal cells, is primarily involved in 
the desmoplastic reaction, but it may also support or 
antagonize cancer cell survival and dissemination [18, 21]. 
These dual TGFβ1 effects depend on the status of cancer 
cells and on the intracellular signalling events evoked 
upon the binding of its receptors. TGFβ1 signalling has 
been previously reported as one of the 12 core signalling 
pathways altered in PDAC [22], and recently it was 
identified as part of a core transcriptional gene program 
including also PDGF, VEGF, Ras, integrin, PI3K/
AKT and Wnt signalling, which increased expression 
characterizes the most lethal PDAC squamous subtype 
[23]. TGFβ1 activates SMAD-dependent canonical and 
SMAD-independent non-canonical signal pathways. 
Canonical TGFβ signalling refers to the receptor-mediated 
carboxy terminal phosphorylation of the receptor-
regulated SMAD2/3 (R-Smads) promoting binding to the 
common mediator SMAD4 (Co-Smad), and the further 
translocation of the heterocomplex in the nucleus thus 
initiating the transcription of extracellular matrix proteins, 
such as fibronectin, collagen and proteoglycans [24]. The 
canonical TGFβ signalling pathway is regulated by the 
inhibitor Smads (I-Smads) SMAD6 and SMAD7, which 
act by inhibiting R-Smads by competitive binding with 
SMAD4 [24]. Non-canonical TGFβ signalling activates 
different pathways like JNK, MAPK/ERK, PI3K/AKT 
and NF-κB. Multiple mechanisms are implicated in 
non-canonical TGFβ signalling, including the imbalance 
between the TGFβ1 receptors, TβRI and TβRII, and 
the tyrosine phosphorylation of the cytoplasmic tail of 
TβRII in the activation of ERK, MAPK or JNK. It is not 
yet completely understood the mechanism underlying 
PI3K/AKT and NF-κB pathways activation [25–27]. 
The activation of non-canonical MAPK/ERK, JNK or 
AKT signalling pathways might prevent canonical TGFβ 
signalling because they regulate stability, activity and 
nuclear transport of R-Smads through the phosphorylation 
of the serine/threonine residues of the linker region [24]. 
Since SMAD4 plays a crucial role in the canonical 
TGFβ signalling pathway, SMAD4 gene deletion should 
necessarily determine an altered cellular response to 
TGFβ1 stimulation. As is the case for TGFβ1, the calcium 
binding proteins S100A8/A9 are dual faced molecules that 
are not only involved in PDAC growth and dissemination, 
but can also form complexes with TGFβ1 thus concurring 
in further enhancing the spectrum of the effects evoked 
in cancer cells by this cytokine [28]. The expression of 
S100A8/A9 is also intimately linked with SMAD4 status: 
it is prevalent in stromal cells when cancer cells express 
SMAD4, whereas in SMAD4 homozygous deletion cancer 
cells independently acquire the ability to express S100A8/
A9 [29–31]. Through the engagement of RAGE and 
TLR4, S100A8/A9 receptors activate several intracellular 
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signalling pathways, such as NF-κB, MAPK/ERK and 
JNK [32].
Due to their relevance in cancer biology, therapeutic 
targeting of EGF, but also of PI3K/AKT/mTOR pathways, 
appears a promising treatment strategy [33, 34]. However, 
any benefit from targeted therapy for PDAC in clinical 
practice has, so far, only been minor in terms of disease 
free survival and overall survival [33, 35]. One of the 
reasons for treatment failure might be resistance to 
targeted therapies developed by tumor cells, since they not 
only accumulate genetic defects during tumor progression 
but they also adapt to a changing microenvironment. 
Adaptation might lead to activation of alternative growth 
factor receptor pathways or it may be the result of 
constitutively activated downstream intracellular signals, 
being an increased expression of the EGF receptor 
signalling pathway a signature of the most aggressive 
PDAC subtype [23]. 
The present “in vitro” study was made in order to 
assess whether the exposure of cancer cells to EGF in 
the tumor microenvironment modifies pancreatic cancer 
cell signalling, proliferation and invasion in response to 
EGF itself, TGFβ1 and S100A8/A9 singly or combined 
and whether SMAD4 has a part in this scenario. By using 
a microarray system that enables us to simultaneously 
analyse multiple signalling pathways, we demonstrated 
that in cells without SMAD4 expression, TGFβ1 and 
S100A8/A9 inhibit NF-κB and PI3K/AKT pathways. 
Chronic EGF stimulation enhanced cell invasion, 
possibly through MMP9 expression, while flattening the 
overall cell signalling response to the studied stimuli in a 
SMAD4-independent manner.
RESULTS
Characterization of the cellular model
BxPC3 cells, HD for SMAD4, and BxPC3-
SMAD4+, a SMAD4 transfected BxPC3 cell clone, were 
used in this study. By RT-PCR BxPC3-SMAD4+ cells 
were found to express SMAD4 mRNA (mean CT ± SD 
of 4 independent experiments each made in duplicate = 
20.81 ± 0.56) at levels higher than those of the SMAD4+ 
cell lines MiaPaCa2 (24.70 ± 0.39) and Panc1 (25.25 ± 
0.46). SMAD4 expression was not detected in BxPC3 
cells (CT always above 30). Supplementary Figure 1 
shows the melting curves of a representative experiment. 
Smad4 protein was evidenced by western blot analysis 
in the cell lines used as positive controls (MiaPaCa2 and 
Panc1), but not in BxPC3 nor in BxPC3-SMAD4+ cells 
(Supplementary Figure 1). To assess whether SMAD4 
mRNA expression has an impact on the cellular proteome, 
the expression of BxPC3 and BxPC3-SMAD4+ cellular 
proteins was compared by means of SILAC experiments. 
Based on the results of two independent experiments, a 
total of 1476 and 1102 proteins were identified by means 
of Proteome Discoverer software. The results of the two 
experiments were matched and averaged, this resulting in a 
total of 1002 proteins reported in Supplementary Table 1. A 
significant differential expression was considered when the 
ratio between BxPC3 and BxPC3-SMAD4+ for any protein 
was below 0.67 (underexpressed in BxPC3, n = 26 proteins) 
or above 1.5 (overexpressed in BxPC3, n = 89 proteins).
SMAD4 HD enables the constitutive and 
EGF-induced activation of multiple signalling 
pathways 
The effects of SMAD4 on cell signalling in response 
to chronic EGF stimulation were first investigated. 
To obtain a comprehensive overview of intracellular 
signalling pathways, RPPA analysis was performed 
comparing BxPC3 and BxPC3-SMAD4+, cultured in 
the absence or in the presence of 100 ng/mL EGF for 
three days. RPPA results (Table 1) showed that SMAD4 
expression impacts on PI3K/AKT, ERK and NF-κB 
pathways, while EGF and SMAD4 interact and impact 
on MAP kinase, ERK and apoptosis pathways. RPPA 
data were confirmed by the western blot analyses of the 
representative targets, p-AKT (Thr308 and Ser473), and 
p-Iκ-Bα (Ser32) (Supplementary Figure 2). The mTOR 
and Wnt/β-catenin pathways were also investigated in 
the above-described conditions, by means of p-mTOR 
(Ser2481 and Ser2448) and p-β-catenin (Ser33/37/Thr41) 
analyses (Supplementary Figure 2). Independently from 
SMAD4 expression, the exposure of cells to EGF chronic 
stimulation caused both increased (Ser2448) and decreased 
mTOR (Ser2481) phosphorylation, while p-β-catenin was 
induced in BxPC3 but not in BxPC3-SMAD4+ cells.
TGFβ1 and S100A8/A9 inhibits NF-κB and AKT 
pathways and concurs with EGF in inhibiting 
apoptosis 
The EGF-evoked cancer cell response might have 
depended not only on the mutational status of cancer 
cells, but also on the interactions between EGF and 
other stimuli, which are likely to occur in the tumor 
microenvironment. To investigate the effects of these 
interactions on cell signalling, RPPA experiments were 
performed considering BxPC3 and BxPC3-SMAD4+ 
cells subjected or not to chronic EGF pre-treatment, and 
acutely stimulated with EGF, TGFβ1 and S100A8/A9 
alone or combined. The overall RPPA results are reported 
in Table 2. Representative targets of the most affected 
pathways are shown in Figure 1 (ERK and NF-κB), Figure 
2 (PI3K/AKT) and Figure 3 (IL1β and apoptosis). EGF, as 
expected, induced ERK phosphorylation in both BxPC3-
SMAD4+ and BxPC3 cells. On chronic exposure of cells 
to EGF pre-treatment, EGF in a single dose did not induce 
further ERK phosphorylation, as confirmed by western blot 
(Figure 4). In BxPC3 cells, TGFβ1 and S100A8/A9, alone 
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Table 1: Reverse phase protein array (RPPA) data obtained from unstimulated and from EGF 
chronically stimulated pancreatic cancer cells expressing (BxPC3-SMAD4+) or not (BxPC3) 
SMAD4
TNF receptor 1 pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
TRAF2 0.45 0.7241 0.3106 0.7728 0.7721
p-RIP2 (Ser176) 2.14 0.1739 0.1330 0.1304 0.4062
A20/TNFAIP3 0.61 0.6256 0.3606 0.3739 0.9184
NF-kB pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
p-IKKα/β (Ser176/Ser177) 5.56 0.0233 0.8008 0.0039 0.4736
IKKα 1.07 0.4154 0.6599 0.1222 0.9356
IKKβ 3.16 0.0858 0.1434 0.0310 0.9011
p-NF-kB p65 (Ser536) 3.48 0.0703 0.3467 0.0280 0.1700
PI3K/AKT pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
SHIP2 1.56 0.2736 0.0868 0.9416 0.3810
p-eNOS (Ser1177) 1.69 0.2455 0.6894 0.0603 0.7372
p-AKT (Thr308) 9.80 0.0047 0.3509 0.0007 0.6495
p-AKT (Ser473) 1.53 0.2806 0.5316 0.0759 0.9763
PI3K p85 4.62 0.0371 0.5307 0.0064 0.9064
PI3K p100a 1.95 0.2005 0.6238 0.0535 0.5140
p-GSK3b (Ser9) 3.97 0.0527 0.3360 0.0109 0.9584
p-PTEN (Ser380) 4.65 0.0366 0.3266 0.0247 0.0515
MAP kinase pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
p-HSP27 (Ser82) 9.37 0.0054 0.4823 0.1388 0.0011
p-p38 MAPK (Thr180/Thr182) 2.41 0.1426 0.6049 0.1035 0.0961
c-Jun pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
p-SAPK/JNK
(Thr183/Tyr185) 1.49 0.2901 0.3928 0.1014 0.6526
MKK7 7.29 0.0112 0.1370 0.0099 0.0233
ERK pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
MEK1/2 0.60 0.6344 0.5322 0.3011 0.7145
p-MEK1/2 (Ser217/Ser221) 2.27 0.1572 0.1269 0.1359 0.3119
ERK1/2 12.91 0.0020 0.3133 0.0011 0.0076
p-ERK1/2 (Thr202/Tyr204) 42.18 < 0.0001 0.3334 0.0025 < 0.0001
SRC/JAK/STAT pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
p-STAT3 (Tyr705) 4.40 0.0417 0.0122 0.6376 0.1482
SOCS3 1.96 0.1990 0.6011 0.1415 0.1261
IL-1b pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
TRAF6 2.84 0.1060 0.9780 0.0595 0.0909
p-TAK1 (Ser412) 3.50 0.0696 0.8759 0.0386 0.0702
Inflammasome pathway Model EGF SMAD4 EGF and SMAD4 
F value p value p value p value p value
p-STAT1 (Tyr701) 3.75 0.0599 0.1726 0.0449 0.1036
Apoptosis pathway Model EGF SMAD4 EGF and SMAD4 
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or combined, inhibited NF-κB, AKT and IL-1β pathways 
and reduced BAD phosphorylation, thus favouring its 
pro-apoptotic effect; all these effects were abolished 
by chronic EGF pre-treatment. In SMAD4 expressing 
BxPC3-SMAD4+ cells, combined S100A8/A9 and EGF 
treatment inhibited NF-κB [p-IKKα/β (Ser176/Ser177), 
IKKα, IKKβ, p-NF-κB p65 (Ser536)] and AKT [p-AKT 
(Thr308), p-AKT (Ser473), PI3K p100a, PI3K p85] pathways. 
These effects were reversed by EGF pre-treatment. 
Smad2 and Smad3 phosphorylation in whole cell lysates 
were also evaluated in the above described conditions 
and results are shown in Supplementary Figure 3. 
Both proteins were expressed in BxPC3 and BxPC3-
SMAD4+ cells and their expression was independent from 
stimuli. Smad2 and Smad3 phosphorylation was never 
found. The same results were obtained by the analysis of 
nuclear extracts (not shown). The mTORC pathway was 
also investigated by western blot (Supplementary Figure 3). 
All studied molecules induced the phosphorylation of 
mTOR, mainly at the Ser2481 site, and to a greater extent 
in BxPC3 than in BxPC3-SMAD4+ cells. The Wnt/β-
catenin pathway was studied by the analysis of the nuclear 
accumulation of p-β-catenin (Ser35/37/Thr41) (Figure 5), 
which was induced by all stimuli in both BxPC3 and 
F value p value p value p value p value
BCL-2 1.24 0.3582 0.1910 0.8625 0.2361
p-BAD (Ser136) 8.60 0.0069 0.4614 0.1038 0.0016
The cells were cultured for three days in the absence or in the presence of 100 ng/mL EGF which was added daily. For any target the percentage changes 
in fluorescence intensity relative to untreated BxPC3 were calculated from three independent experiments. EGF pre-treated and non pre-treated BxPC3 and 
BxPC3-SMAD4+ cells were compared with each other by the analysis of variance (ANOVA) including in the model the effects of EGF, SMAD4 and of 
their interaction.
Figure 1: ERK and NF-κB pathways. Representative data from Reverse Phase Protein Array (RPPA) analysis obtained from 
unstimulated and from EGF chronically stimulated pancreatic cancer cells expressing (BxPC3-SMAD4+) or not (BxPC3) SMAD4. The 
cells were cultured for three days in the absence or in the presence of 100 ng/mL EGF which was added daily. At the fourth day the cells 
were stimulated with EGF 100 ng/mL, TGFβ1 0.02 ng/mL and S100A8/A9 10 nM alone or combined, and with insulin 50 mU or they were 
left untreated. The percentage changes in fluorescence intensity relative to BxPC3 without EGF pre-treatment (control) were calculated and 
reported as mean ± SD (three independent experiments). * = statistically significant with respect to control.
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Table 2: Reverse phase protein array (RPPA) data obtained from unstimulated and from EGF 
chronically stimulated pancreatic cancer cells expressing (BxPC3-SMAD4+) or not (BxPC3) 
SMAD4
BxPC3 BxPC3-SMAD4+ Pre-treated BxPC3
Pre-treated BxPC3-
SMAD4+
TNF receptor 1 pathway F value p value F value p value F value p value F value p value
A20/TNFAIP3 0.30 0.9258 0.67 0.6788 0.57 0.7481 1.29 0.3225
TRAF2 2.54 0.0710 0.80 0.5862 1.03 0.4476 1.33 0.3076
p-RIP2 (Ser176) 1.42 0.2755 0.82 0.5723 0.36 0.8945 1.18 0.3703
NF-kB pathway F value p value F value p value F value p value F value p value
p-IKKα/β
(Ser176/Ser177) 6.52 0.0019 1.72 0.1893 1.46 0.2618 2.18 0.1071
IKKα 5.57 0.0039 0.42 0.8569 0.79 0.5945 0.24 0.9566
p-NF-kB p65(Ser536) 11.29 0.0001 0.55 0.7614 0.38 0.8777 0.84 0.5597
IKKβ 3.08 0.0389 2.21 0.1036 0.46 0.8284 0.31 0.9228
PI3K/AKT pathway F value p value F value p value F value p value F value p value
SHIP2 2.79 0.0531 0.34 0.9026 0.20 0.9726 0.68 0.6702
p-eNOS (Ser1177) 9.34 0.0003 0.62 0.7132 0.16 0.9832 0.70 0.6513
p-AKT(Thr308) 13.68 0.0000 0.64 0.6990 0.85 0.5510 1.40 0.2816
p-AKT(Ser473) 1.60 0.2182 0.89 0.5267 1.15 0.3862 0.35 0.8953
PI3K p85 5.26 0.0050 0.44 0.8420 0.97 0.4816 1.10 0.4093
PI3K p100a 6.82 0.0015 0.69 0.6641 1.28 0.3288 0.54 0.7717
p-GSK3b (Ser9) 1.45 0.2652 1.21 0.3584 0.74 0.6252 0.77 0.6079
p-PTEN (Ser380) 0.72 0.6373 0.50 0.7977 1.15 0.3858 0.19 0.9732
MAP kinase pathway F value p value F value p value F value p value F value p value
p-HSP27(Ser82) 2.34 0.0891 1.77 0.1768 0.88 0.5331 1.17 0.3763
p-p38 MAPK (Thr180/Thr182) 0.70 0.6575 0.87 0.5386 1.04 0.4386 0.98 0.4743
c-Jun pathway F value p value F value p value F value p value F value p value
p-SAPK/JNK
(Thr183/Tyr185) 1.60 0.2181 1.73 0.1870 0.60 0.7290 2.29 0.0946
MKK7 2.26 0.0982 1.32 0.3119 2.19 0.1065 0.29 0.9323
ERK pathway F value p value F value p value F value p value F value p value
MEK1/2 0.30 0.9267 0.47 0.8196 0.66 0.6799 0.44 0.8391
p-MEK1/2 (Ser217/Ser221) 0.85 0.5545 0.69 0.6590 0.15 0.9853 1.39 0.2838
ERK1/2 4.06 0.0145 2.53 0.0718 3.08 0.0390 0.10 0.9955
p-ERK1/2 (Thr202/Tyr204) 6.65 0.0017 2.41 0.0818 0.52 0.7850 0.74 0.6288
SRC/JAK/STAT pathway F value p value F value p value F value p value F value p value
p-STAT3
(Tyr705) 1.70 0.1932 1.36 0.2974 1.59 0.2207 0.40 0.8681
SOCS3 1.07 0.4255 0.23 0.9602 0.64 0.6938 0.43 0.8497
IL-1b pathway F value p value F value p value F value p value F value p value
TRAF6 4.15 0.0133 2.15 0.1122 1.67 0.2020 0.17 0.9820
p-TAK1 (Ser412) 1.67 0.2004 3.56 0.0237 0.43 0.8436 0.19 0.9752
Inflammasome pathway F value p value F value p value F value p value F value p value
p-STAT1(Tyr701) 1.75 0.1808 0.96 0.4874 1.32 0.3124 0.56 0.7530
Apoptosis pathway F value p value F value p value F value p value F value p value
BCL-2 1.40 0.2821 1.37 0.2913 0.71 0.6489 1.10 0.4077
p-BAD(Ser136) 3.08 0.0390 0.83 0.5673 5.33 0.0047 0.36 0.8930
The cells were cultured for three days in the absence or in the presence of 100 ng/mL EGF which was added daily. For any target the percentage changes 
in fluorescence intensity relative to untreated BxPC3 were calculated from three independent experiments. EGF pre-treated and non pre-treated BxPC3 and 
BxPC3-SMAD4+ cells were compared with each other by the analysis of variance (ANOVA) including in the model the effects of EGF, TGFβ1, S100A8/
A9 alone or combined and of insulin.
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BxPC3-SMAD4+ cells. Chronic exposure to EGF 
abolished p-β-catenin nuclear accumulation in BxPC3 and 
caused a reduced p-β-catenin nuclear accumulation after 
stimuli in BxPC3-SMAD4+, not in BxPC3.
Chronic EGF stimulation enhances cell 
migration and MMP9 expression, not cell 
proliferation
Matrigel invasion assays were performed in order 
to verify whether the above-described alterations in 
cell signalling had an impact on cell biology. Chronic 
EGF stimulation significantly increased the number of 
migrating BxPC3-SMAD4+, but mainly BxPC3 cells 
(One-way ANOVA: F = 3.99, p = 0.0123) (Figure 6). The 
95th percentile value of untreated BxPC3 and BxPC3-
SMAD4+ migrating cells was 3,412 cells/well. This value 
was used as a threshold to classify the number of migrating 
cells found in any experimental set as “comparable to” 
or “higher than” control cells. The percentage of BxPC3 
and BxPC3-SMAD4+ experimental sets with a number 
of migrating cells higher than 3,412 cells/well is reported 
in Figure 7. In BxPC3-SMAD4+ cells, stimulation with 
S100A8/A9, EGF and TGFβ1 alone or combined caused 
a significant increase in migration (X2 = 15.4256, p = 
0.017). In BxPC3 cells all stimuli increased the number of 
migrating cells with respect to control cells although not 
to a significant extent (X2 = 7.2738, p = 0.296). In EGF 
pre-treated BxPC3-SMAD4+ and BxPC3 cells, the studied 
stimuli neither enhanced nor reduced migrating cell 
numbers with the exception of EGF and TGFβ1 inhibitory 
effects in BxPC3 (X2 = 3.6008, p = 0.731 and X2 = 9.4574, 
p = 0.149, respectively).
Neither SMAD4 expression nor EGF chronic 
stimulation affected cell proliferation (F = 1.34, p = 
0.2655). Only co-stimulation with S100A8/A9 and EGF 
caused a slight increase of BxPC3 cell proliferation 
(Supplementary Table 2).
Figure 2: PI3K/AKT pathway. Representative data from Reverse Phase Protein Array (RPPA) analysis obtained from unstimulated 
and from EGF chronically stimulated pancreatic cancer cells expressing (BxPC3-SMAD4+) or not (BxPC3) SMAD4. The cells were 
cultured for three days in the absence or in the presence of 100 ng/mL EGF which was added daily. At the fourth day the cells were 
stimulated with EGF 100 ng/mL, TGFβ1 0.02 ng/mL and S100A8/A9 10 nM alone or combined, and with insulin 50 mU or they were left 
untreated. The percentage changes in fluorescence intensity relative to BxPC3 without EGF pre-treatment (control) were calculated and 
reported as mean ± SD (three independent experiments). * = statistically significant with respect to control.
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The relative expression of the metalloproteinases 
MMP8 and MMP9 was evaluated in the above-described 
conditions. Non-stimulated and stimulated BxPC3-
SMAD4+ and BxPC3 cells did not express MMP8 (mean 
Ct > 40 cycles). Both BxPC3-SMAD4+ and BxPC3 cells 
expressed MMP9, which was significantly induced by a 
single acute stimulation with EGF alone or combined with 
S100A8/A9 in both cell lines (Two-way Anova: SMAD4 
effect: F = 12.46, p < 0.0001; Treatment effect: F = 68.39, 
p < 0.0001; Interaction: F = 5.56, p = 0.114) (Figure 8). 
EGF pre-treatment caused in BxPC3 an increased (almost 
twice) and in BxPC3-SMAD4+ a decreased (almost half) 
MMP9 expression with respect to untreated BxPC3, and 
reduced in both cell lines the response to stimuli  (Two-
way Anova: SMAD4 effect: F = 55.52, p < 0.0001; 
Treatment effect: F = 13.92, p = 0.042; Interaction: F = 
5.21, p = 0.470).
DISCUSSION
EGFR overexpression is known to play a pivotal 
role in many cancer types including pancreatic carcinoma 
[36]. Based on this premise, several EGFR targeted 
therapies have been developed, and their use has been 
approved for the treatment of patients [37]. Yet these 
therapeutic approaches are often unsuccessful, particularly 
in pancreatic cancer patients [38]. This failure depends on 
several factors, including the complexity of the genetic 
alterations and tumor heterogeneity, the plasticity of 
tumor cells that enable them to activate alternative 
signalling pathways when one of them is antagonized, 
and the multiplicity of inflammatory molecules and 
growth factors from the stromal compartment, which 
might support EGFR-independent tumor cell growth 
and invasion [4, 20, 23, 39–41]. The aim of the present 
study was to improve our understanding of the way in 
which EGF governs the pancreatic cancer cell response to 
relevant stromal derived molecules, TGFβ1 and S100A8/
A9, while also investigating whether SMAD4 participates 
in this complex scenario. The cellular model used in this 
study gave us the opportunity to investigate the role of 
SMAD4 mRNA, expressed by BxPC3-SMAD4+ but not 
by BxPC3 cells, independently from Smad4 protein, which 
was not expressed by any of our cell lines. Although it is 
unclear why SMAD4 translation did not occur in BxPC3-
SMAD4+ cells, the results obtained in this study clearly 
Figure 3: IL-1β and apoptosis pathways. Representative data from Reverse Phase Protein Array (RPPA) analysis obtained from 
unstimulated and from EGF chronically stimulated pancreatic cancer cells expressing (BxPC3-SMAD4+) or not (BxPC3) SMAD4. The 
cells were cultured for three days in the absence or in the presence of 100 ng/mL EGF which was added daily. At the fourth day the cells 
were stimulated with EGF 100 ng/mL, TGFβ1 0.02 ng/mL and S100A8/A9 10 nM alone or combined, and with insulin 50 mU or they were 
left untreated. The percentage changes in fluorescence intensity relative to BxPC3 without EGF pre-treatment (control) were calculated and 
reported as mean ± SD (three independent experiments). * = statistically significant with respect to control.
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indicate that SMAD4 transcripts regulate several SMAD4-
related cellular patterns thus deciphering new roles for 
this relevant tumor suppressor gene. We first analyzed 
by RPPA a series of signalling pathways in pancreatic 
cancer cells, expressing or not expressing SMAD4, and 
repeatedly stimulated with EGF “in vitro” in order to 
simulate “in vivo” conditions. EGF chronic stimulation and 
SMAD4 were found to interact in the activation of ERK, 
MAP kinase and apoptosis pathways. In particular chronic 
exposure to EGF induced ERK and MAPK activation, 
and inhibited apoptosis in SMAD4 expressing cells [20]. 
EGF chronic stimulation exerted SMAD4-independent 
activation of SRC/JAK/STAT pathway and inhibition 
of the Wnt/β-catenin cascade. EGF chronic stimulation 
was also associated with an increased matrigel invasion, 
but not with an increased cellular proliferation in both 
SMAD4 expressing or not expressing cells in agreement 
with previous findings from Levy and Hill [42], thus 
supporting the hypothesis that EGF exacerbates pancreatic 
cancer progression and that therapeutic strategies aiming 
to block the EGF-EGFR axis are potentially beneficial. 
The increased tumor invasion is the end result of increased 
transcription of pro-survival and pro-invasive genes, 
including matrix metalloproteinases 8 and 9, which are 
believed to play a relevant role [43–45]. In the present 
study we demonstrated that MMP9, not MMP8, is induced 
by chronic EGF in SMAD4 non-expressing cells and 
inhibited in SMAD4 expressing cells. This highlights 
MMP9 as a potential target for further intervention at least 
in the subset of cancers carrying SMAD4 HD.
In the pancreatic cancer microenvironment, 
several tumor and stromal derived molecules target 
cancer cells, and cross-talk between the respectively 
activated pathways occurs [20]. A deleterious cross-
talk between EGF and TGFβ pathways, enhanced by 
SMAD4 mutations, has been described by Deharvengt 
et al. [46], who studied a series of pancreatic cancer cell 
lines with a different SMAD4 profile. With respect to 
the above-cited study, our experimental model allows a 
clearer definition of the role of SMAD4 expression, the 
Figure 4: Western blot analyses obtained from pancreatic cancer cells expressing (BxPC3-SMAD4+) or not (BxPC3) 
SMAD4 and subjected to insulin (INS), EGF, TGFβ1 and S100A8/A9 stimulation in the absence or in the presence of 
chronic EGF exposure. Representative targets of the ERK (panels A and B), NF-ĸB (panels C and D), PI3K/AKT (panels E and F) 
pathways are shown.
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Figure 5: Wnt/β-catenin pathway. Western blot analyses of nuclear p-β-catenin and of  β-catenin obtained from pancreatic cancer 
cells expressing (BxPC3-SMAD4+) or not (BxPC3) SMAD4 and subjected to insulin (INS), EGF, TGFβ1 and S100A8/A9 stimulation in 
the absence or in the presence of chronic EGF exposure. 
Figure 6: Matrigel invasion obtained from unstimulated and from EGF chronically stimulated pancreatic cancer 
cells expressing (BxPC3-SMAD4+) or not (BxPC3) SMAD4. Columns represent mean values, bars represent standard deviations 
obtained from four independent experiments each made in triplicate. 
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only one genetic difference between BxPC3 and BxPC3-
SMAD4+ cells. TGFβ1 had only modest, if any, effect on 
cell signalling in SMAD4 expressing cells. By contrast, 
TGFβ1 caused a significant inhibition of NF-κB, PI3K/
AKT and IL-1β pathways in the case of SMAD4 loss. 
These findings suggest that SMAD4 mRNA expression 
antagonizes TGFβ1-induced engagement of non-SMAD 
pathways, those most privileged being NF-κB, PI3K/
AKT and IL-1β [26, 47, 48]. The cross-talk between EGF 
and TGFβ1 signalling was also supported by the results 
obtained in EGF pre-treated cells, which became almost 
insensitive to the inhibitory effects on cell signalling of 
TGFβ1 in a SMAD4-independent manner. Moreover, 
EGF and TGFβ join forces on cell migration: TGFβ1 
enhanced cell migration independently from SMAD4 
status in EGF non-pretreated cells, but had the opposite 
effect on EGF pre-treated cells. These findings appear 
in disagreement with those of Levy and Hill [42], who 
demonstrated that SMAD4 silencing completely abolished 
TGFβ1 induced migration and this discrepancy might 
depend on differences between the cellular models and 
TGFβ1 dosages. We used low amounts of TGFβ1 (0.02 
ng/mL) because they were comparable to those used by 
Yasutome et al. [49], they were previously demonstrated 
by us to induce the epithelial to mesenchymal transition 
in BxPC3 [28] and they were consistent with the amount 
released by pancreatic tumor cells [50]. Although the 
low TGFβ1 dosage might be unable to induce Smad2/3 
phosphorylation, never observed in our experimental 
conditions, a potential disruption in the TGFβ receptors 
might also be hypothesized [51]. The above observations 
regarding TGFβ1 could be translated to the heterocomplex 
Figure 7: Matrigel invasion obtained from pancreatic cancer cells expressing (BxPC3-SMAD4+) or not (BxPC3) 
SMAD4 and subjected to insulin, EGF, TGFβ1 and S100A8/A9 stimulation in the absence or in the presence of chronic 
EGF exposure. Columns represent the percentage of experiments with a number of migrating cells higher than 95th percentile of their 
respective control cells. Four independent experiments, each made in triplicate, were performed resulting in 12 replicates for any studied 
condition. 
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S100A8/A9, since almost all the effects exerted by TGFβ1 
on cell signalling, including the cross-talk with EGF 
signalling, and those on cell invasion were reproduced by 
the treatment of cells with S100A8/A9, thus confirming 
the existence of a biological similarity between TGFβ1 
and S100A8/A9 as previously demonstrated by us in 
the context of epithelial to mesenchymal transition [28]. 
Interestingly, a potential anti-apoptosis effect through the 
induction of p-BAD [52], was obtained in case of SMAD4 
not expressing cells when co-stimulated with both 
molecules and chronically exposed to EGF. This means 
that SMAD4 expression can prevent the activation of pro-
survival pathways when cells are exposed to S100A8/A9 
in the presence of TGFβ1 and EGF. From a mechanistic 
viewpoint, we suggest that SMAD4 HD, which correlates 
with tumor progression, creates a favorable ground for 
the activation of pro-survival pathways when multiple 
inflammatory stimuli, which are likely to occur in the 
tumor microenvironment, target cancer cells.
In the present study we also ascertained the effects of 
insulin, since it has been suggested that hyperinsulinemia 
due to insulin resistance is a risk factor for pancreatic 
cancer in patients with longstanding diabetes mellitus, 
while in those with early onset diabetes mellitus, it is 
considered a consequence of pancreatic cancer itself 
[53, 54]. Insulin did not influence any studied signaling 
pathways, but it favored matrigel invasion of BxPC3. 
This finding indicates that insulin probably accelerates 
pancreatic cancer progression in SMAD4 not expressing 
cells. Whether or not insulin is per se carcinogenetic is an 
open question.
It remains to be elucidated how SMAD4 mRNA, 
independently from Smad4 protein expression, might 
have a so relevant impact on cell signalling and cell 
migration. We verified whether SMAD4 expression 
caused differentially expressed proteins in the two studied 
cell lines. Among proteins underexpressed in BxPC3, we 
found Serum deprivation-response protein (SDPR), in 
Figure 8: Matrix metalloproteinase 9 (MMP9) mRNA relative expression obtained from pancreatic cancer cells 
expressing (BxPC3-SMAD4+) or not (BxPC3) SMAD4  and subjected to insulin, EGF, TGFβ1 and S100A8/A9 
stimulation in the absence or in the presence of chronic EGF exposure. Columns represent mean values, bars represent standard 
errors obtained from three independent experiments each made in triplicate and report the relative mRNA fold increase with respect to 
BxPC3 without EGF pre-treatment. **= p < 0.01 with respect to unstimulated and TGFβ1 and S100A8/A9 stimulated BxPC3 cells; *= p < 
0.05 with respect to unstimulated and TGFβ1 and S100A8/A9 stimulated BxPC3-SMAD4+ cells.
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line with findings by Fullerton et al. [55] who compared 
BxPC3 and BcPC3-p-INS4c5, a stable clone of BxPC3 
expressing Smad4 protein, and showed SDPR mRNA as 
the most de-regulated gene. In BxPC3 we found a reduced 
expression of EGFR, this suggesting once again a link 
between the EGF and TGFβ pathways, and of Caveolin-1 
(CAV1), which activates NF-κB [56], this being in line 
with the observed inhibition of this signalling pathway 
observed in this cell line. A role for differently expressed 
microRNA might also be hypothesized, since both 
canonical and non-canonical TGFβ signalling have been 
shown to be dependent on and to interact with several 
microRNA [57]. We focused our attention on miRNA 133a 
and miRNA 199, since they target the EGFR and Smad4 
respectively [58, 59]. We observed that miRNA 133a 
expression was SMAD4 dependent, values being higher in 
BxPC3-SMAD4+ cells exposed or not exposed to chronic 
EGF (2.5 fold increase by RT-PCR), while miRNA 199 
was both EGF and SMAD4 dependent, being induced by 
EGF chronic treatment in BxPC3 (3.3 fold increase by 
RT-PCR), not in BxPC3-SMAD4+ cells. This supports 
the hypothesis that SMAD4 expression might impact on 
signalling pathways like ERK through the de-regulation 
of microRNA [58].
In conclusion, SMAD4 homozygous deletion favors 
the constitutive activation of ERK, the EGF-induced 
activation of NF-κB and PI3K/AKT, and the EGF-induced 
inhibition of Wnt/β-catenin pathways, which are critical to 
cancer proliferation and metastases. TGFβ1 and S100A8/
A9, which share their overall effects on pancreatic cancer 
cells, mainly inhibit NF-κB and PI3K/AKT in a SMAD4-
dependent manner. The cross-talk between TGFβ1, 
S100A8/A9 and EGF signalling results in an overall 
de-sensitization of cancer cells to TGFβ1 and S100A8/
A9 stimuli when chronically exposed to EGF, with the 
exception of the apoptosis pathway, the inhibition of BAD 
persisting in response to the combined action of TGFβ1 
and S100A8/A9 in an SMAD-4 dependent manner. These 
pathways may be therefore potential targets for further 
therapeutic interventions.
MATERIALS AND METHODS
Cell lines
The pancreatic cancer cell line BxPC3 was kindly 
donated by Dr Andrea Galli (University of Florence, 
Italy). BxPC3-SMAD4+ cell line was obtained after clonal 
selection of BxPC3 cells transfected with the expression 
vector pBK-cytomegalovirus (CMV)-SMAD4/DPC4, 
as described by us elsewhere [28]. MiaPaCa2 were 
purchased by the American Type Culture Collection 
(Manassas, VA, USA) and Panc1 cells were donated by 
Prof Aldo Scarpa (University of Verona, Italy). MiaPaCa2 
cells were cultured in DMEM while all the other cell 
lines were cultured in RPMI (Gibco, Life Technologies, 
Monza, Italy) supplemented with 10% fetal calf serum 
(FCS) (Gibco, Life Technologies, Monza, Italy), 2% 
L-Glutamine (MiaPaCa2) or 1% L-glutamine (all the 
other cell lines) (Gibco, Life Technologies, Monza, Italy) 
and 0.1% gentamycin (Gibco, Life Technologies, Monza, 
Italy). 
SMAD4 Real time (RT)-PCR
RT-PCR was used to verify the mRNA expression 
of SMAD4 gene. RNA was extracted from 1x106 
cells (MagnaPure Compact RNA isolation kit, Roche, 
Monza, Italy). One microgram of total RNA was reverse 
transcribed into cDNA (Random primers and Superscript 
TM II RNasiH-Reverse Trascriptase, Life Technologies, 
Monza, Italy). SMAD4 was PCR amplified (ABI 
Prism 7900 HT, Applied Biosystems, CA, USA) with 
40 ng cDNA, 12.5 pmol/μL each of the primers pair 
5′CCCAGGATCAGTAGGTGGAA3′ (Forward, exon 10) 
and 5′AAGGTTGTGGGTCTGCAATC3′ (Reverse 
exon 11), in a final volume of 20 μL containing MgCl 25 
mM, dNTP 5 mM, EvaGreen 20× (Biotium, Inc., Hayward, 
CA, USA), SuperTaq 1 Unit (AB Analitica, Padova, Italy). 
After denaturation (5 minutes at 94°C), 30 amplification 
cycles (94°C for 30 seconds, 57°C for 30 seconds and 
72°C for 30 seconds) were run. In all runs a positive 
control was always used (cDNA from 1x106 MiaPaca2 and 
PANC cell lines). Each sample was analyzed in duplicate.
SILAC experiment (Cell culture, In-gel 
digestion, LC-MS/MS and data analysis)
In a first experiment, BxPC3 and BxPC3-SMAD4+ 
cell lines were cultured in RPMI 1640 MEDIA FOR 
SILAC with 10% dialyzed fetal bovine serum (FBS), 
additioned either with the non-labelled aminoacids Lysin 
and Arginine (light medium) or with the labelled 13C6-
Lysine and 13C6
15N4-arginine (heavy medium) (Chemical 
Research 2000 srl, Rome, Italy). In a second experiment, 
the same cell lines were cultured by swapping media, 
being the BxPC3 maintained in heavy medium and 
BxPC3-SMAD4+ maintained in light medium, creating 
two biological replicates of the same experiment. After 
8 days, cell media were changed with freshly media 
prepared as specified above excluding the serum addition, 
to reduce the possible amount of contaminant in proteomic 
analyses. 
Ten μg of proteins of each biological replicate were 
loaded onto a precast gel (NuPAGE, 4–12% Bis-Tris, 
Life Technologies, Monza, Italy) and electrophoresis 
was carried out. Each lane was then divided into 4 slices 
which were then subjected to reduction/alkylation and 
in-gel digestion with sequencing grade modified trypsin 
(Promega, Madison, WI, USA) as previously described 
[60]. Peptides were extracted from the gel by 3 changes 
of 50% acetonitrile/0.1% formic acid (FA). Samples were 
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dried under vacuum, suspended in 3% acetonitrile/0.1% 
FA and loaded into a 10 cm pico-frit column (75 um 
I.D., 15 um Tip, New Objective, Woburn, MA, USA) 
packed in-house with C18 material (Aeris Peptide 3.6 um 
XB-C18, Phenomenex, Bologna, Italy). Peptides were 
separated with a HPLC Ultimate 3000 (Dionex – Thermo 
Fisher Scientific, Waltham, MA, USA) using a linear 
gradient from 3 to 50% of acetonitrile/0.1 FA in 90 min 
at a flow rate of 250 nL/min. LC-MS/MS analysis was 
conducted with a LTQ-Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific). Data were analyzed with 
the Proteome Discoverer software (version 1.4, Thermo 
Fisher Scientific) interfaced to a Mascot server (version 
2.2.4, Matrix Science, London, UK) and searched against 
the human section of the Uniprot Database (www.
uniprot.org, version 20150401, 90411 sequences) using 
carbamidomethyl cysteine as static modification and 13C6-
Lysine, 13C6
15N4-arginine, and methionine oxidation as 
variable modifications. Precursor and fragment tolerance 
were set at 10 ppm and 0.6 Da, respectively. Samples 
were searched using a MudPIT protocol and the algorithm 
Percolator was used to calculate False Discovery 
Rate (FDR) based on the search against a randomized 
database. The results were filtered in order to consider 
only proteins identified with at least two unique peptides 
and high confidence (q < 0.01). Only unique peptides were 
considered for quantification. The ratio between light/
heavy and heavy/light were calculated for each identified 
protein of the two experiments. Proteins were considered 
as significantly altered if the average value, calculated for 
the two ratios, was either above 1.5 or less than 0.67. 
Experimental design
BxPC3 and BxPC3-SMAD4+ were cultured for 3 
days in the absence and in the presence of 100 ng/mL EGF 
(ProSpec-Tany TechnoGene Ltd., D.B.A. Italia, Segrate, 
Italy). Fresh media with or without EGF were daily 
replaced. On the fourth day (experimental day) the cells 
were not stimulated (negative control) or were stimulated 
with 100 ng/mL EGF, 0,02 ng/mL TGFβ1 (ProSpec-Tany 
TechnoGene Ltd., D.B.A. Italia, Segrate, Italy), 10 nM 
S100A8/A9 (ProSpec-Tany TechnoGene Ltd., D.B.A. 
Italia, Segrate, Italy), or with 50 mU insulin (positive 
control) (Insuman Rapid, Sanofi-Aventis, Milano, Italy). 
For RPPA and immunoblot analyses the cells were 
collected ten minutes after stimulation. For Matrigel 
invasion assay and matrix metalloproteinases expression 
the cells were collected 24 hours after stimulation. Cell 
proliferation was evaluated 72 hours after stimulation.
Reverse phase protein array (RPPA) analysis
RPPA analysis was performed using a procedure 
previously optimized and validated [61]. Briefly, cell 
lysates obtained from 800,000 cells (ø 10 cm Petri 
dishes) were solubilized in 4×SDS loading buffer (Sigma-
Aldrich, Milano, Italy) and heated for 5 minutes at 95°C. 
Samples were spotted in duplicates onto nitrocellulose-
coated glass slides (Grace Bio-labs, Bend, OR, USA) 
using a microarraying robot (MicroGrid 610, Digilab, 
Marlborough, MA, USA). The printed slides were 
blocked and incubated overnight at 4°C with shaking with 
the specific primary antibodies (Supplementary Table 3) 
(Cell Signalling Technology, Danvers, MA, USA). 
β-actin was included as a house-keeping protein to control 
protein loading. After incubation with infrared secondary 
antibodies (800 CW LI-COR anti-rabbit antibody and 
700 CW LI-COR anti-mouse antibody), the slides 
were scanned with a Licor Odyssey scanner (LI-COR, 
Biosciences, Lincoln, NE, USA) at 21 μm resolution at 
700 and 800 nm. The fluorescent data were processed 
with GenePix Pro-6 Microarray Image Analysis software 
(Molecular Services Inc., Sunnyvale, CA, USA). Protein 
signals were determined with background subtraction and 
normalization to the internal housekeeping targets using 
an RPP analyzer.
Immunoblot analysis
For immunoblot analysis, 800,000 cells were used 
(ø 10 cm Petri dishes). Petri dishes were transferred into 
an ice bath, and the cells were washed twice with cold 
PBS, and re-suspended in 100 μL of cold lysis buffer 
[20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1% Triton-X 100, 50 mM NaF, 10 mM Na4P2O7,1 mM 
Na3VO4, and 10% protease inhibitor cocktail (Sigma 
Aldrich SRL, Milano, Italy)]. Lysates were centrifuged 
for 10 minutes at 14,000 rpm at 4°C, and total proteins 
in the supernatants were measured using the Bio-Rad 
protein assay (Bio-Rad Laboratories, Milano, Italy). For 
each sample, 40 μg proteins were electrophoresed through 
4–12% NuPAGE® Novex Bis-Tris SDS–PAGE Gel or 
3–8% NuPAGE® Novex Tris-Acetate SDS–PAGE Gel 
(Life Technologies, Monza, Italy) and electrophoretically 
transferred to Nitrocellulose Membrane (iBlot® Transfer 
Stack, Life Technologies, Monza, Italy) by means of the 
iBlotTM Dry Blotting System (Life Technologies, Monza, 
Italy). Following incubation for 1 hour in a blocking 
buffer [5% low fat powder milk re-suspended in PBS-T 
(PBS with 0.1% Tween-20)], membranes were incubated 
overnight at 4°C with the primary antibodies [anti-
Smad4, anti-phospho-Smad2 (Ser465/467), anti-Smad2, anti-
phospho-Smad3 (Ser423/425), anti-Smad3, anti-phospho-Akt 
(Ser473, Thr308), anti-Akt, anti-β-actin, anti-phospho-mTOR 
(Ser2448, Ser2481), anti-phospho-β catenin (Ser33/37/Thr41), 
anti-β catenin, anti-phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (Cell Signalling Technology, Danvers, 
MA, USA); anti-phospho IkB-α (Ser32) (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA)], diluted 
1:5000 (β-actin), 1:2000 (mTOR) or 1:3000 (all the 
others) in the blocking buffer. The blots, washed three 
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times in PBS-T for 15 minutes each time, were incubated 
with alkaline phosphatase-conjugated anti-rabbit (Cell 
Signalling Technology, Danvers, MA, USA) or anti-goat 
(Sigma-Aldrich, Milano, Italy) secondary antibodies and 
then washed three times in PBS-T for 15 minutes each 
time and developed with the ECL Advance Western Blot 
Detection Kit (GE Healthcare Technologies, Milan, Italy). 
Each experiment was performed at least in triplicate.
Nuclear proteins were extracted by the “NE-
PER nuclear and cytoplasmic extraction reagents” 
(Thermo Scientific, Rockford, IL, USA) following the 
manufacturer’s instructions. Immunoblot analysis of 
nuclear extracts were performed in the same conditions 
described above. 
Matrigel invasion assay
For matrigel invasion experiments twelve-well 
plates (ø 12 mm) with polycarbonate membrane filters 
(Transwell, Corning Costar Corporation, Milano, Italy) 
were used. Matrigel (BD Biosciences, Bedford, MA, 
USA), diluted with cold RPMI to the desired final 
concentration (1.5 μg/μL), was applied (200 μL) to the 
filters and dried overnight in a humidified atmosphere at 
37 °C. For each condition, 100 x 103 cells, suspended in 
500 μL RPMI containing 0.1% bovine serum albumin 
(BSA) (Sigma-Aldrich, Milano, Italy), were loaded on 
the Matrigel layer (upper chamber); corresponding tumor 
conditioned RPMI (700 μL) was added to the lower 
chamber. The cells were then incubated for 48 hours in a 
humidified atmosphere at 37 °C. After Matrigel removal, 
each filter was cut and transferred onto a new well of a 
new plate containing 100 μL Luciferase (Cell Titer-Glo® 
Luminescent Cell Viability Assay, Promega, Madison, 
WI, USA), which allows the detection of viable cells. 
After 10 minutes’ incubation at room temperature in the 
dark, luminescence was measured (counts per second, 
cps) using the multilabel counter Victor3 (Perkin Elmer, 
Waltham, MA, USA). For each condition a series of at 
least three separate experiments, each made in duplicate, 
were performed. In each experiment serial dilutions of a 
known number of BxPC3 and of BxPC3-SMAD4+ cells 
were prepared and analysed as described above to obtain 
a correlation between the number of cells and cps. The 
regression line obtained was used to calculate the number 
of migrating cells based on cps results.
Cell proliferation XTT assay
Cell growth was assessed using the XTT cell viability 
test (Roche Diagnostics S.p.A., Monza, Italy). Briefly, 
2,000 cells per well were seeded in 96-well cell culture 
plates and treated as detailed in the experimental design. 
After 72 hours’ stimulation, 100 μL XTT reagent was added 
to each well, and left for for 4 hours before Abs450nm analysis 
(PR 3100 TSC, Bio-Rad Laboratories, Milano, Italy).
MMP8 and MMP9 mRNA expression analyses 
For expression analyses 150,000 cells seeded 
in six-well plates were used. Total RNA was isolated 
(High Pure RNA Isolation Kit, Roche Diagnostics 
S.p.A., Monza, Italy) according to the manufacturer’s 
instructions. Three μg of total RNA was reverse 
transcribed into cDNA (Random primers and Superscript 
II -Reverse Trascriptase, Life Technologies, Monza, 
Italy).The relative quantification of MMP8 and MMP9 
mRNA was undertaken by RT-PCR with an ABI Prism 
7900 HT (Applied Biosystems, CA, USA). Primers 
(MMP8-F: 5′CACTCCCTCAAGATGACATCGA3′-
R:5′ACGGAGTGTGGTGATAGCATCA3′; MMP9-F: 
 5′CCTGGGCAGATTCCAAACCT3′- R: 5′GCAAGTCTT 
CCGAGTAGTTTTGGAT3′) and fluorogenic probes 
(MMP8-5′FAM-CAAGCAACCCTATCCAACCTACTGG 
ACCAA-TAMRA3′; MMP9-5′FAM-CTCAAGTGGCACC 
ACCACAACATCACC-MGB3′) for relative quantifications 
were performed in a final volume of 20 μL for MMP8 and 
MMP9. For each reaction, 150 ng cDNA, 200 nM probe 
and 500 nM (MMP8/MMP9) primers were used. The 
reference gene, HPRT1, was selected according to the 
method commonly used for internal control for quantitative 
gene expression analyses, and its expression was 
determined using commercially available HPRT1 primers 
and probe sets (PDARs part number 4326321E, Applied 
Biosystems, CA, USA). MMP8, MMP9 and HPRT1 were 
analyzed in triplicate for each sample. MMP8 and MMP9 
PCR reactions were 2 minutes at 50°C and 10 minutes at 
95°C respectively, followed by 40 cycles of 15 seconds 
at 95°C and 1 minute at 60°C. To determine the relative 
RNA of target genes levels we used the comparative Ct 
method, a mathematical model that calculates changes in 
gene expression as a relative fold difference between an 
experimental and a calibrator sample.
Statistical analysis
The statistical analysis of data was made by the 
Analysis of variance, Bonferroni’s test for pairwise 
comparisons and the chi-square test using Stata Ver. 13.1 
(StataCorp, Texas, USA).
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